FcRn阻断剂治疗后甲状腺功能正常及Graves甲亢长期缓解:一例病例报告
本文报告一例55岁女性Graves病患者,在接受甲巯咪唑15-25 mg/日治疗15个月后仍甲状腺功能亢进,遂于临床研究中使用研究性FcRn阻断剂batoclimab。开始每周皮下注射batoclimab后1周内血清FT3和FT4恢复正常,4周内TSH正常,第6周停用甲巯咪唑;停用batoclimab后23个月患者仍保持甲状腺功能正常且未用甲巯咪唑,TSH-R-Ab持续低于正常上限。结论提示FcRn阻断可能对Graves病有效并可能改变疾病进程。
要点
- FcRn阻断剂batoclimab可在1周内使FT3和FT4正常化,4周内TSH正常。
- 停用batoclimab后23个月患者仍维持甲状腺功能正常且未用甲巯咪唑。
- TSH-R-Ab在停用batoclimab后23个月仍低于正常上限。
核心结论
- FcRn阻断可能对Graves病有效并可能改变疾病进程。
研究设计与样本
- 病例报告:一例55岁女性Graves病患者,有17个月病史,接受甲巯咪唑15-25 mg/日治疗15个月后仍甲状腺功能亢进,随后在临床研究中接受研究性FcRn阻断剂batoclimab并继续临床随访。
主要发现
- 开始每周皮下注射batoclimab后1周内血清FT3和FT4恢复正常。
- TSH在4周内恢复正常,甲巯咪唑在研究第6周停用。
- 停用batoclimab后23个月,患者仍未用甲巯咪唑,FT3、FT4和TSH均正常。
- 停用batoclimab后18个月总IgG恢复至近似基线水平,而基线升高的TSH-R-Ab在停用后23个月仍低于正常上限。
临床怎么用
- 对于甲巯咪唑治疗下仍甲状腺功能亢进的Graves病患者,FcRn阻断剂batoclimab可能作为研究性治疗选择。
- 使用batoclimab期间需监测甲状腺功能及TSH-R-Ab,停用甲巯咪唑后继续随访甲状腺功能。
局限性
- 本文为单例病例报告,结论需在更大规模研究中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neonatal fragment crystallizable receptor (FcRn) blockers selectively inhibit FcRn-mediated IgG recycling, resulting in degradation of IgG autoantibodies, including thyrotropin receptor autoantibodies (TSH-R-Ab). METHODS: We describe a case involving a 55-year-old woman with a 17-month history of Graves' disease (GD) who was hyperthyroid despite 15 months on methimazole (MMI) 15-25 mg/day. She received the investigational FcRn blocker batoclimab in a clinical study and was subsequently followed in clinic. RESULTS: Within 1 week of starting weekly subcutaneous batoclimab, serum free triiodothyronine (FT3) and thyroxine (FT4) were normalized. Thyrotropin (TSH) was normal within 4 weeks. MMI was discontinued by study week 6. Twenty-three months after stopping batoclimab, the patient remained off MMI, with normal FT3, FT4, and TSH. Total IgG returned to approximate baseline levels 18 months post discontinuation of batoclimab, whereas TSH-R-Ab, which was elevated at baseline, remained below the upper limit of normal 23 months post batoclimab discontinuation. CONCLUSIONS: FcRn blockade may be an effective and potentially disease-modifying treatment for GD.
引用
- Kahaly GJ, Wolf J, Luffy M, et al. Euthyroidism and Long-Term Remission of Graves' Hyperthyroidism Following Treatment With an FcRn Blocker: A Case Report. Thyroid. 2026. PMID: 41684304. doi:10.1177/10507256261423190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。